{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"383.95","value":"16.52"},{"groupId":"OG001","spread":"194.65","value":"4.40"},{"groupId":"OG002","spread":"412.75","value":"2.26"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"15"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"430.86","value":"32.48"},{"groupId":"OG001","spread":"97.21","value":"6.76"},{"groupId":"OG002","spread":"473.58","value":"8.51"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"Cycle 3 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"15"}],"units":"Participants"}],"description":"Ctrough is the lowest observed serum concentration.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Dose Escalation: Uninfected hepatocellular carcinoma (HCC) participants received nivolumab 0.1/0.3/1/3/10 mg/kg every 2 weeks","id":"OG000","title":"Cohort 1 Uninfected HCC"},{"description":"Dose Escalation: Hepatitis C (HCV)-infected participants received nivolumab 0.3/1/3 mg/kg every 2 weeks","id":"OG001","title":"Cohort 1 HCV Infected"},{"description":"Dose Escalation: Hepatitis B (HBV)-infected participants received nivolumab 0.1/0.3/1/3 mg/kg every 2 weeks","id":"OG002","title":"Cohort 1 HBV Infected"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All treated participants in Cohort 1 with baseline and at least 1 post-baseline assessment; uninfected HCC, HCV-infected, and HBV-infected participants reported together as pre-specified.","reportingStatus":"POSTED","timeFrame":"At Cycle 1 Day 1 and Cycle 3 Day 1 (Each Cycle = 2 Weeks)","title":"Serum Concentration Achieved at the End of Dosing Interval (Trough Concentration) (Ctrough)","type":"SECONDARY","unitOfMeasure":"ug/mL"}